Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Latest From Brian Yang

China's New Hong Kong Security Law To Derail Biotech IPOs?

A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.

Financing Hong Kong

Global Supply Chain In Historic Upheaval As 'De-China' Trend Marches On

More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.

China Manufacturing

China Tightens Clinical Study Grip In Sweeping Biosecurity Law Proposal

From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.

China Legislation

No Love From US: Senate Bill Deals Blow To Aspiring China Biotechs

In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.

Policy & Regulation Financing

China Bioventures' Role In Virus Fight Helps Secure $721m In New Funding, Deals

Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.

Deals Financing

China-US Virus Showdown Creating Health Policy Uncertainties

China has stepped up its support for the World Health Organization just as the US is ratcheting up its criticism of both the global health body and China, as policy observers watch closely for any signs the tense bilateral relationship may spill over to the health sector.

China United States
See All
UsernamePublicRestriction

Register